Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epetraborole in Phlebotomy-Dependent Polycythemia Vera
NCT07891533Phase 2Not yet recruiting
- Sponsor
- AN2 Therapeutics, Inc.
- Start
- Nov 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of epetraborole in polycythemia vera (PV) (5 arms), sponsored by AN2 Therapeutics, Inc. Primary endpoint: Proportion of Participants Maintaining Clinical Success. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
epetraborole
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT07891533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07891533.